Clinical Trials
18 trialsNCT06961006 2026-04-13
INTerpath-012
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT04305054 2026-04-08
KEYMAKER-U02
Merck Sharp & Dohme LLC
Phase 1/2 Active not recruiting
NCT03820986 2026-02-09
LEAP-003
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04889118 2025-12-23
LEAP-003
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04700072 2025-10-28
KEYMAKER-U02
Merck Sharp & Dohme LLC
Phase 1/2 Completed
NCT04303169 2025-10-27
KEYMAKER-U02
Merck Sharp & Dohme LLC
Phase 1/2 Completed
NCT05665595 2025-10-15
KEYVIBE-010
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03715205 2025-08-29
Keynote-593
Merck Sharp & Dohme LLC
Phase 4 Completed
NCT04305041 2025-08-29
KEYMAKER-U02
Merck Sharp & Dohme LLC
Phase 1/2 Completed
NCT03783078 2025-05-28
KEYNOTE-913
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03553836 2024-11-29
KEYNOTE-716
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT04152863 2024-08-06
V937-011
Merck Sharp & Dohme LLC
Phase 2 Terminated
NCT05709821 2024-04-24
IMM60 and Pembrolizumab in Melanoma and NSCLC
Portage Biotech
Phase 1/2 Terminated
NCT02130466 2022-08-01
MK-3475-022
Merck Sharp & Dohme LLC
Phase 1/2 Completed
NCT01866319 2020-06-02
MK-3475-006
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03361228 2020-05-21
A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors
Incyte Corporation
Phase 1/2 Terminated
NCT01704287 2020-05-18
KEYNOTE 002
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT01295827 2019-12-13
KEYNOTE-001
Merck Sharp & Dohme LLC
Phase 1 Completed